{"product_id":"protein-analysis-using-mass-spectrometry-9781118605196","title":"Protein Analysis using Mass Spectrometry","description":"\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eList of Contributors xiii\u003c\/p\u003e \u003cp\u003eForeword xvii\u003c\/p\u003e \u003cp\u003ePreface xix\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Contemporary Protein Analysis by Ion Mobility Mass Spectrometry 1\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eJohannes P.C. Vissers and James I. Langridge\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 1\u003c\/p\u003e \u003cp\u003e1.2 Traveling-Wave Ion Mobility Mass Spectrometry 1\u003c\/p\u003e \u003cp\u003e1.3 IM–MS and LC–IM–MS Analysis of Simple and Complex Mixtures 2\u003c\/p\u003e \u003cp\u003e1.4 Outlook 7\u003c\/p\u003e \u003cp\u003eAcknowledgment 8\u003c\/p\u003e \u003cp\u003eReferences 8\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 High-Resolution Accurate Mass Orbitrap and Its Application in Protein Therapeutics Bioanalysis 11\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eHongxia Wang and Patrick Bennett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 11\u003c\/p\u003e \u003cp\u003e2.2 Triple Quadrupole Mass Spectrometer and Its Challenges 11\u003c\/p\u003e \u003cp\u003e2.3 High-Resolution Mass Spectrometers 12\u003c\/p\u003e \u003cp\u003e2.4 Quantitation Modes on Q Exactive Hybrid Quadrupole Orbitrap 13\u003c\/p\u003e \u003cp\u003e2.5 Protein Quantitation Approaches Using Q Exactive Hybrid Quadrupole Orbitrap 14\u003c\/p\u003e \u003cp\u003e2.6 Data Processing 16\u003c\/p\u003e \u003cp\u003e2.7 Other Factors That Impact LC–MS-based Quantitation 16\u003c\/p\u003e \u003cp\u003e2.8 Conclusion and Perspectives of LC–HRMS in Regulated Bioanalysis 18\u003c\/p\u003e \u003cp\u003eReferences 18\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Current Methods for the Characterization of Posttranslational Modifications in Therapeutic Proteins Using Orbitrap Mass Spectrometry 21\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eZhiqi Hao, Qiuting Hong, Fan Zhang, Shiaw-Lin Wu, and Patrick Bennett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 21\u003c\/p\u003e \u003cp\u003e3.2 Characterization of PTMs Using Higher-Energy Collision Dissociation 23\u003c\/p\u003e \u003cp\u003e3.3 Application of Electron Transfer Dissociation to the Characterization of Labile PTMs 26\u003c\/p\u003e \u003cp\u003e3.4 Conclusion 31\u003c\/p\u003e \u003cp\u003eAcknowledgment 32\u003c\/p\u003e \u003cp\u003eReferences 32\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Macro- to Micromolecular Quantitation of Proteins and Peptides by Mass Spectrometry 35\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eSuma Ramagiri, Brigitte Simons, and Laura Baker\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 35\u003c\/p\u003e \u003cp\u003e4.2 Key Challenges of Peptide Bioanalysis 36\u003c\/p\u003e \u003cp\u003e4.3 Key Features of LC\/MS\/MS-Based Peptide Quantitation 38\u003c\/p\u003e \u003cp\u003e4.4 Advantages of the Diversity of Mass Spectrometry Systems 41\u003c\/p\u003e \u003cp\u003e4.5 Perspectives for the Future 41\u003c\/p\u003e \u003cp\u003eReferences 42\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Peptide and Protein Bioanalysis Using Integrated Column-to-Source Technology for High-Flow Nanospray 45\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eShane R. Needham and Gary A. Valaskovic\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction – LC–MS Has Enabled the Field of Protein Biomarker Discovery 45\u003c\/p\u003e \u003cp\u003e5.2 Integration of Miniaturized LC with Nanospray ESI-MS Is a Key for Success 46\u003c\/p\u003e \u003cp\u003e5.3 Micro- and Nano-LC Are Well Suited for Quantitative Bioanalysis 47\u003c\/p\u003e \u003cp\u003e5.4 Demonstrating Packed-Emitter Columns Are Suitable for Bioanalysis 49\u003c\/p\u003e \u003cp\u003e5.5 Future Outlook 51\u003c\/p\u003e \u003cp\u003eReferences 52\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Targeting the Right Protein Isoform: Mass Spectrometry-Based Proteomic Characterization of Alternative Splice Variants 55\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eJiang Wu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 55\u003c\/p\u003e \u003cp\u003e6.2 Alternative Splicing and Human Diseases 55\u003c\/p\u003e \u003cp\u003e6.3 Identification of Splice Variant Proteins 56\u003c\/p\u003e \u003cp\u003e6.4 Conclusion 64\u003c\/p\u003e \u003cp\u003eReferences 64\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 The Application of Immunoaffinity-Based Mass Spectrometry to Characterize Protein Biomarkers and Biotherapeutics 67\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eBradley L. Ackermann and Michael J. Berna\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 67\u003c\/p\u003e \u003cp\u003e7.2 Overview of IA-MS Methods 69\u003c\/p\u003e \u003cp\u003e7.3 IA-MS Applications – Biomarkers 74\u003c\/p\u003e \u003cp\u003e7.3.1 Peptide Biomarkers 74\u003c\/p\u003e \u003cp\u003e7.4 IA-MS Applications – Biotherapeutics 81\u003c\/p\u003e \u003cp\u003e7.5 Future Direction 84\u003c\/p\u003e \u003cp\u003eReferences 85\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Semiquantification and Isotyping of Antidrug Antibodies by Immunocapture-LC\/MS for Immunogenicity Assessment 91\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eJianing Zeng, Hao Jiang, and Linlin Luo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 91\u003c\/p\u003e \u003cp\u003e8.2 Multiplexing Direct Measurement of ADAs by Immunocapture-LC\/MS for Immunogenicity Screening, Titering, and Isotyping 93\u003c\/p\u003e \u003cp\u003e8.3 Indirect Measurement of ADAs by Quantifying ADA Binding Components 95\u003c\/p\u003e \u003cp\u003e8.4 Use of LC–MS to Assist in Method Development of Cell-Based Neutralizing Antibody Assays 96\u003c\/p\u003e \u003cp\u003e8.5 Conclusion and Future Perspectives 97\u003c\/p\u003e \u003cp\u003eReferences 97\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Mass Spectrometry-Based Assay for High-Throughput and High-Sensitivity Biomarker Verification 99\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eXuejiang Guo and Keqi Tang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Background 99\u003c\/p\u003e \u003cp\u003e9.2 Sample Processing Strategies 100\u003c\/p\u003e \u003cp\u003e9.3 Advanced Electrospray Ionization Mass Spectrometry Instrumentation 102\u003c\/p\u003e \u003cp\u003e9.4 Conclusion 105\u003c\/p\u003e \u003cp\u003eReferences 105\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Monitoring Quality of Critical Reagents Used in Ligand Binding Assays with Liquid Chromatography Mass Spectrometry (LC–MS) 107\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eBrian Geist, Adrienne Clements-Egan, and Tong-Yuan Yang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 107\u003c\/p\u003e \u003cp\u003e10.2 Case Study Examples 114\u003c\/p\u003e \u003cp\u003e10.3 Discussion 122\u003c\/p\u003e \u003cp\u003eAcknowledgment 126\u003c\/p\u003e \u003cp\u003eReferences 126\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Application of Liquid Chromatography-High Resolution Mass Spectrometry in the Quantification of Intact Proteins in Biological Fluids 129\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eStanley (Weihua) Zhang, Jonathan Crowther, and Wenying Jian\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 129\u003c\/p\u003e \u003cp\u003e11.2 Workflows for Quantification of Proteins Using Full-Scan LC-HRMS 131\u003c\/p\u003e \u003cp\u003e11.3 Internal Standard Strategy 133\u003c\/p\u003e \u003cp\u003e11.4 Calibration and Quality Control (QC) Sample Strategy 135\u003c\/p\u003e \u003cp\u003e11.5 Common Issues in Quantification of Proteins Using LC-HRMS 135\u003c\/p\u003e \u003cp\u003e11.6 Examples of LC-HRMS-Based Intact Protein Quantification 137\u003c\/p\u003e \u003cp\u003e11.7 Conclusion and Future Perspectives 138\u003c\/p\u003e \u003cp\u003eAcknowledgment 140\u003c\/p\u003e \u003cp\u003eReferences 140\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 LC–MS\/MS Bioanalytical Method Development Strategy for Therapeutic Monoclonal Antibodies in Preclinical Studies 145\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eHongyan Li, Timothy Heath, and Christopher A. James\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction: LC-MS\/MS Bioanalysis of Therapeutic Monoclonal Antibodies 145\u003c\/p\u003e \u003cp\u003e12.2 Highlights of Recent Method Development Strategies 146\u003c\/p\u003e \u003cp\u003e12.3 Case Studies of Preclinical Applications of LC–MS\/MS for Monoclonal Antibody Bioanalysis 154\u003c\/p\u003e \u003cp\u003e12.4 Conclusion and Future Perspectives 156\u003c\/p\u003e \u003cp\u003eReferences 158\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Generic Peptide Strategies for LC–MS\/MS Bioanalysis of Human Monoclonal Antibody Drugs and Drug Candidates 161\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eMichael T. Furlong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 161\u003c\/p\u003e \u003cp\u003e13.2 A Universal Peptide LC–MS\/MS Assay for Bioanalysis of a Diversity of Human Monoclonal Antibodies and Fc Fusion Proteins in Animal Studies 161\u003c\/p\u003e \u003cp\u003e13.3 An Improved “Dual” Universal Peptide LC–MS\/MS Assay for Bioanalysis of Human mAb Drug Candidates in Animal Studies 165\u003c\/p\u003e \u003cp\u003e13.4 Extending the Universal Peptide Assay Concept to Human mAb Bioanalysis in Human Studies 170\u003c\/p\u003e \u003cp\u003e13.5 Internal Standard Options for Generic Peptide LC–MS\/MS Assays 173\u003c\/p\u003e \u003cp\u003e13.6 Sample Preparation Strategies for Generic Peptide LC–MS\/MS Assays 175\u003c\/p\u003e \u003cp\u003e13.7 Limitations of Generic Peptide LC–MS\/MS Assays 177\u003c\/p\u003e \u003cp\u003e13.8 Conclusion 178\u003c\/p\u003e \u003cp\u003eAcknowledgments 178\u003c\/p\u003e \u003cp\u003eReferences 178\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Mass Spectrometry-Based Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugate Candidates During Drug Development 183\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eYongjun Xue, Priya Sriraman, Matthew V. Myers, Xiaomin Wang, Jian Chen, Brian Melo, Martha Vallejo, Stephen E. Maxwell, and Sekhar Surapaneni\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 183\u003c\/p\u003e \u003cp\u003e14.2 Mechanism of Action 183\u003c\/p\u003e \u003cp\u003e14.3 Mass Spectrometry Measurement for DAR Distribution of Circulating ADCs 186\u003c\/p\u003e \u003cp\u003e14.4 Total Antibody Quantitation by Ligand Binding or LC–MS\/MS 189\u003c\/p\u003e \u003cp\u003e14.5 Total Conjugated Drug Quantitation by Ligand Binding or LC–MS\/MS 193\u003c\/p\u003e \u003cp\u003e14.6 Catabolite Quantitation by LC–MS\/MS 196\u003c\/p\u003e \u003cp\u003e14.7 Preclinical and Clinical Pharmacokinetic Support 197\u003c\/p\u003e \u003cp\u003e14.8 Conclusion and Future Perspectives 198\u003c\/p\u003e \u003cp\u003eReferences 198\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Sample Preparation Strategies for LC–MS Bioanalysis of Proteins 203\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eLong Yuan and Qin C. Ji\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 203\u003c\/p\u003e \u003cp\u003e15.2 Sample Preparation Strategies to Improve Assay Sensitivity 205\u003c\/p\u003e \u003cp\u003e15.3 Sample Preparation Strategies to Differentiate Free, Total, and ADA-Bound Proteins 213\u003c\/p\u003e \u003cp\u003e15.4 Sample Preparation Strategies to Overcome Interference from Antidrug Antibodies or Soluble Target 214\u003c\/p\u003e \u003cp\u003e15.5 Protein Digestion Strategies 214\u003c\/p\u003e \u003cp\u003e15.6. Conclusion 215\u003c\/p\u003e \u003cp\u003eAcknowledgment 216\u003c\/p\u003e \u003cp\u003eReferences 216\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Characterization of Protein Therapeutics by Mass Spectrometry 221\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eWei Wu, Hangtian Song, Thomas Slaney, Richard Ludwig, Li Tao, and Tapan Das\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 221\u003c\/p\u003e \u003cp\u003e16.2 Variants Associated with Cysteine\/Disulfide Bonds in Protein Therapeutics 221\u003c\/p\u003e \u003cp\u003e16.3 N–C-Terminal Variants 225\u003c\/p\u003e \u003cp\u003e16.4 Glycation 226\u003c\/p\u003e \u003cp\u003e16.5 Oxidation 226\u003c\/p\u003e \u003cp\u003e16.6 Discoloration 228\u003c\/p\u003e \u003cp\u003e16.7 Sequence Variants 230\u003c\/p\u003e \u003cp\u003e16.8 Glycosylation 232\u003c\/p\u003e \u003cp\u003e16.9 Conclusion 240\u003c\/p\u003e \u003cp\u003eReferences 240\u003c\/p\u003e \u003cp\u003eIndex 251\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":51769056002391,"sku":"9781118605196","price":144.35,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781118605196.jpg?v=1758719481","url":"https:\/\/bookcurl.com\/products\/protein-analysis-using-mass-spectrometry-9781118605196","provider":"Book Curl","version":"1.0","type":"link"}